UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection

Circulation research, 2016-01, Vol.118 (1), p.145-156

Ridker, Paul M

2016

Volltextzugriff (PDF)

Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis

Circulation research, 2019-02, Vol.124 (3), p.437-450

Ridker, Paul M

2019

Volltextzugriff (PDF)

Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease

Circulation research, 2021-05, Vol.128 (11), p.1728-1746

2021

Volltextzugriff (PDF)

A Test in Context: High-Sensitivity C-Reactive Protein

Journal of the American College of Cardiology, 2016-02, Vol.67 (6), p.712-723

Ridker, Paul M

2016

Volltextzugriff (PDF)

Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin

European heart journal, 2016-06, Vol.37 (22), p.1720-1722

Ridker, Paul M

2016

Volltextzugriff (PDF)

Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week

Journal of the American College of Cardiology, 2018-12, Vol.72 (25), p.3320-3331

Ridker, Paul M

2018

Volltextzugriff (PDF)

How Common Is Residual Inflammatory Risk?

Circulation research, 2017-02, Vol.120 (4), p.617-619

Ridker, Paul M

2017

Volltextzugriff (PDF)

Should Aspirin Be Used for Primary Prevention in the Post-Statin Era?

The New England journal of medicine, 2018-10, Vol.379 (16), p.1572-1574

Ridker, Paul M

2018

Volltextzugriff (PDF)

From CANTOS to CIRT to COLCOT to Clinic: Will All Atherosclerosis Patients Soon Be Treated With Combination Lipid-Lowering and Inflammation-Inhibiting Agents?

Circulation (New York, N.Y.), 2020-03, Vol.141 (10), p.787-789

Ridker, Paul M

2020

Volltextzugriff (PDF)

From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?

Cardiovascular research, 2021-09, Vol.117 (11), p.e138-e140

Ridker, Paul M

2021

Volltextzugriff (PDF)

The Time to Initiate Anti-Inflammatory Therapy for Patients With Chronic Coronary Atherosclerosis Has Arrived

Circulation (New York, N.Y.), 2023-10, Vol.148 (14), p.1071-1073

Ridker, Paul M

2023

Volltextzugriff (PDF)

Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week

Journal of the American College of Cardiology, 2023-08, Vol.82 (7), p.648-660

2023

Volltextzugriff (PDF)

LDL cholesterol: controversies and future therapeutic directions

The Lancet (British edition), 2014-08, Vol.384 (9943), p.607-617

Ridker, Paul M, Dr Prof

2014

Volltextzugriff (PDF)

Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week

Journal of the American College of Cardiology, 2018-10, Vol.72 (17), p.2071-2081

2018

Volltextzugriff (PDF)

COVID-19 – A vascular disease

Trends in cardiovascular medicine, 2021-01, Vol.31 (1), p.1-5

2021

Volltextzugriff (PDF)

Inhibiting Interleukin-6 to Reduce Cardiovascular Event Rates: A Next Step for Atherothrombosis Treatment and Prevention

Journal of the American College of Cardiology, 2021-04, Vol.77 (15), p.1856-1858

Ridker, Paul M

2021

Volltextzugriff (PDF)

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events

The New England journal of medicine, 2019-02, Vol.380 (8), p.752-762

2019

Volltextzugriff (PDF)

C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: Moving an inflammatory hypothesis toward consensus

Journal of the American College of Cardiology, 2007-05, Vol.49 (21), p.2129-2141

RIDKER, Paul M

2007

Volltextzugriff (PDF)

Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis

European heart journal, 2020-06, Vol.41 (23), p.2153-2163

2020

Volltextzugriff (PDF)

Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents

European heart journal, 2016-05, Vol.37 (17), p.1373-1379

2016

Volltextzugriff (PDF)

A multivariate genome-wide association analysis of 10 LDL subfractions, and their response to statin treatment, in 1868 Caucasians

PloS one, 2015-04, Vol.10 (4), p.e0120758-e0120758

2015

Volltextzugriff (PDF)

Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)

Journal of thrombosis and haemostasis, 2009-07, Vol.7, p.332-339

RIDKER, PAUL M.

2009

Volltextzugriff (PDF)

Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease

The New England journal of medicine, 2016-12, Vol.375 (24), p.2349-2358

2016

Volltextzugriff (PDF)

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

The Lancet (British edition), 2012-08, Vol.380 (9841), p.565-571

2012

Volltextzugriff (PDF)

Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention

Vascular pharmacology, 2023-12, Vol.153, p.107238-107238, Article 107238

Ridker, Paul M

2023

Volltextzugriff (PDF)

1 – 25 von 1.127

Suche als RSS-Feed

Aktive Filter

ThemaProspective Studies

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.077)
Mit Volltextzugriff
(920)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.127)
Japanisch
(173)
Norwegisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(682)
Life Sciences & Biomedicine
(661)
Humans
(648)
Female
(351)
Cardiovascular System & Cardiology
(332)
Cardiac & Cardiovascular Systems
(286)
Risk Factors
(286)
Middle Aged
(278)
Male
(268)
Biological And Medical Sciences
(261)
Medical Sciences
(254)
Aged
(189)
Cardiovascular Disease
(168)
Cardiology. Vascular System
(147)
Inflammation
(140)
Peripheral Vascular Disease
(136)
General & Internal Medicine
(132)
Medicine, General & Internal
(132)
Cholesterol
(125)
Atherosclerosis
(117)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(18)
... seit 30 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection

Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis

Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease

A Test in Context: High-Sensitivity C-Reactive Protein

Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin

Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week

How Common Is Residual Inflammatory Risk?

Should Aspirin Be Used for Primary Prevention in the Post-Statin Era?

From CANTOS to CIRT to COLCOT to Clinic: Will All Atherosclerosis Patients Soon Be Treated With Combination Lipid-Lowering and Inflammation-Inhibiting Agents?

From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?

The Time to Initiate Anti-Inflammatory Therapy for Patients With Chronic Coronary Atherosclerosis Has Arrived

Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week

LDL cholesterol: controversies and future therapeutic directions

Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week

COVID-19 – A vascular disease

Inhibiting Interleukin-6 to Reduce Cardiovascular Event Rates: A Next Step for Atherothrombosis Treatment and Prevention

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events

C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: Moving an inflammatory hypothesis toward consensus

Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis

Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents

A multivariate genome-wide association analysis of 10 LDL subfractions, and their response to statin treatment, in 1868 Caucasians

Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)

Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention

Aktive Filter

Suchergebnisse filtern